OakChart

Jaguar Health Inc

JAGXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.4824+0.0457 (10.46%)
2026-11-12 05:20 CET
Market cap
1.12 USD m
Revenue, TTM
27.82 USD m
Net income, TTM
-52.42 USD m
Free cash flow, TTM
-6.73 USD m
EPS diluted, TTM
-5,482.20
P/E
-
Compare

Price

JAGX against its 20, 50 and 200-day averages
2050200earnings
0.00200.00400.0020.8M41.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JAGXclose 0.4820-day 1.6650-day 3.42200-day 74.010.48

99.9% under the 52-week high of 751.88 on 17 Nov 2025. 52-week low 0.36 on 6 Nov 2026. Last 15 sessions, 652.2% high to low

Volume 0.34× normal · the line is the 50-bar volume average

Profile

JAGX
52-week range, 0% of the way up
0.36751.88

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Employees47
IPOMay 13, 2015
Beta-0.06
ATR, 14d0.65
Rel volume0.34
Insider own6.20%
Inst own0.42%

Snapshot

6 groups

Valuation

Index-
Market Cap6.44M
Enterprise Value16.46M
Income-52.42M
Sales27.82M
Book/sh20.43
Cash/sh0.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees47
IPOMay 13, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S0.23
P/B0.02
P/C0.98
P/FCF-
EV/EBITDA-
EV/Sales0.59
Quick Ratio0.40
Current Ratio0.69
Debt/Eq2.76
LT Debt/Eq0.39
Option/ShortNo / Yes

Earnings

EPS (ttm)-5482.20
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y92.49% 85.33%
Sales past 3/5Y-1.26% 4.17%
EPS Y/Y TTM85.50%
Sales Y/Y TTM135.52%
EPS Q/Q95.63%
Sales Q/Q-58.88%
EarningsAug 19 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own6.20%
Insider Trans0.00%
Inst Own0.42%
Inst Trans0.53%
ROA-88.27%
ROE-498.47%
ROIC-395.01%
Gross Margin75.00%
Oper. Margin-90.22%
Profit Margin-188.46%
SMA20-70.98%
SMA50-85.90%
SMA200-99.35%
Trades-

Technical

Shs Outstand0.32M
Shs Float-
Short Float-
Short Ratio0.07
Short Interest0.20M
52W High751.88 -99.94%
52W Low0.36 34.00%
Volatility19.14% 18.03%
ATR (14)0.65
RSI (14)36.21
Beta-0.06
Rel Volume0.34
Avg Volume3.06M
Volume1,034,964

Performance

Perf Week-3.29%
Perf Month-83.97%
Perf Quarter-94.32%
Perf Half Y-98.66%
Perf YTD-99.86%
Perf Year-99.93%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price2848.04
Prev Close0.44
Price0.48
Change %10.46%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 07, 2021InitiatedCCantor FitzgeraldOverweight$5+936.5%
Jul 11, 2017InitiatedRRodman & RenshawBuy$2+314.6%

Peers

Mkt cap
TickerCompanyMkt cap
ARDXArdelyx Inc786.79M
PALIPalisade Bio Inc203.90M
MCRBSeres Therapeutics Inc15.29M
CTXRCitius Pharmaceuticals Inc13.20M
GUTSFractyl Health Inc11.68M
PHATPhathom Pharmaceuticals Inc510.51M
EDSAEdesa Biotech Inc29.99M
IGCIGC Pharma Inc23.21M
NTRBNutriband Inc72.21M
ORMPOramed Pharmaceuticals Inc171.80M

News

latest 14 of 200
  • Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders (ACCESSWIRE) +7.87%
  • CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE) (ACCESSWIRE) -45.43%
  • Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder (ACCESSWIRE) -13.31%
  • Jaguar Health Provides Update Regarding Special Stock Dividend (ACCESSWIRE) +9.81%
  • Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer (ACCESSWIRE)
  • Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances (InvestorsHub) +18.82%
  • Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi (ACCESSWIRE)
  • Jaguar Health Announces a Special Stock Dividend (ACCESSWIRE) -7.34% +29.23%
  • Napo Pharmaceuticals Crofelemer Study Accepted for Presentation at ACG 2026 (InvestorsHub) -11.63%
  • Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting (ACCESSWIRE)
  • JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: Whats Driving The Surge? (Stocktwits) -74.14%
  • Jaguar Health Receives Fee Waivers from FDA (ACCESSWIRE) +1,190.64%
  • Jaguar Health, Inc. Announces Reverse Stock Split (ACCESSWIRE) -29.57%
  • All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) (ACCESSWIRE) -12.91%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-19-170.34--5,5891.23--
2026Q12026-05-22-204--204.012.03--
2025Q42026-04-074,709--1,7463.24--
2025Q32025-11-17-3,297--3,2973.08--
2025Q22025-08-14-5,387-3,743-5,3842.983.271
2025Q12025-05-15-8,768-5,681-8,7672.212.821
2024Q42025-03-31-7,728-9,713-9,8553.503.101
2024Q32024-11-13-13,781-31,106-13,8033.073.901
2024Q22024-08-13-53,025-15,805-53,0272.723.401
2024Q12024-05-14-47,250-23,625-45,7382.353.001
2023Q42024-04-011,102,500--98,7292.30--
2023Q32023-11-14-299,250-968,625-295,3362.812.461
2023Q22023-08-14-330,750-1,204,875-542,6742.682.281
2023Q12023-05-15-1,882,125--1,880,5891.97--
2022Q42023-03-279,308,250-7,678,125-2,700,9283.302.001
2022Q32022-11-14-7,087,500-4,429,688-6,952,2473.153.552

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY-502,326,562,500-608,373,281,250-334,884,3750.260.30
2016FY-251,162,887,500-241,860,543,750-25.1160.140.20
2018FY-348,173,438-318,937,500-27,158,254,6044.324.44
2019FY-1,596,459,375-1,596,459,375-1,596,051,8465.785.78
2020FY-177,187,500-177,187,500-177,212,3069.409.40
2021FY-69,693,750-42,820,313-69,476,4004.3410.65
2022FY-28,491,750-45,478,125-28,492,93111.9610.60
2023FY-1,409,625--1,409,8859.76-
2024FY-68,644-10,500-68,61111.6911.30
2025FY-9,216-4,720-50,52611.5112.56
2026FY--63.000--2.46
2027FY--141.75--4.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2025-08-061004.244.244.24
2026Q2S2025-08-051004.244.244.24
2026Q2S2025-08-041004.244.244.24
2026Q2S2025-08-031004.244.244.24
2026Q2S2025-08-021004.244.244.24
2026Q2S2025-08-011004.244.244.24
2026Q2S2025-07-311004.244.244.24
2026Q2S2025-07-301004.244.244.24
2026Q2S2025-07-291004.244.244.24
2026Q2S2025-07-281004.244.244.24
2026Q2S2025-07-271004.244.244.24
2026Q2S2025-07-261004.244.244.24
2026Q2S2025-07-251004.244.244.24
2026Q2S2025-07-241004.244.244.24

Estimate history

EPS, annual-9.488-27158254603.722-1596051845.75-177212306.472-69476400.128-28492931.303-1409884.875-68611.069-12059.192-5482.1987
Period201720182019202020212022202320242025TTM
EPS, quarterly-53026.706-13802.775-9855.431-8766.702-5384.08-3296.738-1745.998-204.005-235.459
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual4.3614.4165.7759.3854.33511.9569.76111.68911.51127.82
Period201720182019202020212022202320242025TTM
Sales, quarterly2.7213.1083.5092.2142.9793.0833.23520.2721.225
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual5.6610000000.0010.0130.324
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0010.0010.0010.0010.0030.0070.0130.0250.324
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue27.8211.5111.699.7611.964.339.385.784.42
Cost of Goods Sold Incl. D&A6.955.984.314.424.312.333.283.822.77
Gross Profit20.865.547.385.347.642.006.111.961.65
Selling, General and Administrative Excl. Other45.9650.6438.2139.2642.0641.0827.4126.2627.26
Research and Development25.2324.9716.5418.6017.6515.086.415.825.15
Other Operating Expense0.000.000.000.000.001.635.340.000.00
Operating Income-25.09-45.11-30.83-33.92-34.41-40.71-26.65-24.30-25.61
Interest Expense-0.070.236.3812.728.422.795.732.63
Unusual Expense11.028.878.241.802.212.714.568.584.22
Net Income Before Taxes-36.92-54.00-39.25-41.90-48.40-52.60-33.81-38.53-32.15
Income Taxes0.000.000.000.000.000.000.000.010.00
Consolidated Net Income-36.92-54.00-39.25-41.90-48.40-52.60-33.81-38.54-32.15
Net Income From Continuing Operations-36.40-53.43-38.49-41.30-47.45-52.59-33.81-38.54-32.15
Net Income-52.42-53.58-38.49-41.30-47.45-52.59-38.65-44.73-32.15
EPS (Recurring)-828.80-10,662.40-58,329.77-1,366,892.16-27,565,374.56-66,974,188.26-162,575,083.68-1,381,871,009.99-24,739,081,186.44
EPS (Basic, Before Extraordinaries)-5,482.20-12,059.19-68,611.07-1,409,884.87-28,492,931.30-69,476,400.13-177,212,306.47-1,596,051,845.75-27,158,254,603.72
EPS (Diluted)-5,482.20-12,059.19-68,611.07-1,409,884.87-28,492,931.30-69,476,400.13-177,212,306.47-1,596,051,845.75-27,158,254,603.72
EBITDA-22.93-42.91-28.47-31.53-32.12-38.88-24.37-22.37-23.87
Non-Operating Income (Expense)0.060.040.050.200.95-0.770.190.080.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.580.831.642.113.323.972.822.182.02
Price To Sales Ratio0.090.190.640.360.7110.733.360.690.76
Gross Margin75.0048.0863.1054.6763.9446.1865.0533.9337.37
Operating Margin-90.22-391.87-263.76-347.51-287.85-939.05-283.93-420.75-579.99
Net Margin-188.46-465.42-329.30-423.11-396.91-1,213.26-411.81-774.45-727.92
Shares Outstanding0.320.010.000.000.000.000.000.000.00
Market Capitalization1.121.126.671.885.9926.2547.3321.867.42

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.2320.273.233.082.982.213.513.11
Cost of Goods Sold Incl. D&A1.501.622.741.091.081.061.151.14
Gross Profit-0.2718.650.491.991.901.152.361.97
Selling, General and Administrative Excl. Other7.338.4720.939.239.9010.5710.529.23
Research and Development3.343.9314.313.663.273.734.534.04
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.6010.18-20.44-7.24-8.01-9.42-8.16-7.26
Interest Expense0.160.70-0.01----
Unusual Expense5.420.962.322.312.891.342.563.09
Net Income Before Taxes-12.808.72-23.19-9.65-10.56-10.60-10.23-10.02
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.808.72-23.19-9.65-10.56-10.60-10.23-10.02
Net Income From Continuing Operations-12.688.85-23.06-9.50-10.41-10.46-9.92-9.85
Net Income-12.70-7.01-23.20-9.50-10.41-10.46-9.92-9.85
EPS (Recurring)-165.10-184.36-1,623.68-2,735.72-4,337.48-7,979.09-8,071.61-10,773.97
EPS (Basic, Before Extraordinaries)-235.46-204.00-1,746.00-3,296.74-5,384.08-8,766.70-9,855.43-13,802.77
EPS (Diluted)-235.46-204.00-1,746.00-3,296.74-5,384.08-8,766.70-9,855.43-13,802.77
EBITDA-7.0510.70-19.90-6.68-7.45-8.88-7.56-6.67
Non-Operating Income (Expense)0.380.20-0.43-0.090.340.170.490.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.170.150.120.140.280.300.370.31
Price To Sales Ratio0.090.230.560.300.220.261.141.21
Gross Margin-22.0491.9915.2164.5863.6552.0867.2363.42
Operating Margin-620.1650.23-631.90-234.77-268.78-425.52-232.46-233.66
Net Margin-1,036.82-34.60-717.22-308.21-349.35-472.63-282.70-317.05
Shares Outstanding0.320.020.010.010.000.000.000.00
Market Capitalization1.122.413.254.291.931.606.677.03

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.838.006.475.4717.058.093.882.570.76
Short Term Receivables1.701.652.182.472.144.561.691.000.47
Inventories8.6010.359.197.024.902.782.133.342.07
Other Current Assets2.2212.2010.127.364.342.361.821.240.50
Total Current Assets20.3432.2027.9622.3228.4317.799.528.153.80
Net Property, Plant & Equipment1.461.401.671.701.730.680.710.761.22
Total Investments and Advances0.320.000.000.000.000.000.000.000.00
Intangible Assets16.0218.4820.1222.4422.6524.3426.0231.7138.61
Other Assets0.171.351.010.990.450.040.150.420.00
Total Assets38.3253.4250.7647.4553.2742.8436.4141.0443.63
Short Term Debt Incl. Current Port. of LT Debt27.6312.345.2116.373.423.797.1216.085.42
Accounts Payable8.695.294.975.814.934.765.355.417.35
Other Current Liabilities4.342.083.808.167.124.672.935.162.61
Total Current Liabilities40.6519.7013.9930.3415.4713.2215.3926.6615.39
Long Term Debt15.9724.1931.8818.4725.9412.420.450.0010.98
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.380.550.000.000.000.000.000.000.00
Total Liabilities57.0144.4545.8748.8141.4125.6415.8426.6626.37
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value2.482.480.000.000.000.0011.619.000.00
Common Equity-19.777.294.96-0.6611.6117.208.965.3817.26
Total Shareholders Equity-17.299.774.96-0.6611.6117.2020.5714.3817.26
Accumulated Minority Interest-1.40-0.79-0.06-0.700.240.000.000.000.00
Total Equity-18.698.984.90-1.3611.8517.2020.5714.3817.26
Total Liabilities & Stockholders Equity38.3253.4250.7647.4553.2742.8436.4141.0443.63
Book Value Per Share-1,488.037,237.5753,412.82-234,067.9613,586,950.1626,243,310.2929,095,931.821,029,277,437.863.05
Tangible Book Value Per Share-2,693.65-11,121.12-163,166.95-8,228,353.19-12,918,777.86-10,885,152.87-55,397,214.29-5,033,926,386.23-3.77
Full-Time Employees474949605234294036
Price to Book Ratio0.020.921.381.642.262.752.441.381,490,277,917.80
Return on Assets-116.48-73.89-84.10-94.23-109.45-85.32-99.52-75.93-93.10
Return on Equity--522.60-1,919.14-866.42-365.08-179.03-220.53-203.17-296.74
Return on Invested Capital--113.35-112.11-266.42-140.06-114.13-183.36-223.50-77.78
Quick Ratio0.291.111.340.501.521.140.480.180.11
Current Ratio0.501.632.000.741.841.350.620.310.25

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-37.50-54.41-39.03-41.87-49.08-52.60-33.81-38.54-32.15
Depreciation2.162.202.362.392.291.812.281.931.32
Other Funds (Non Cash)14.3012.0110.3017.3418.1113.5519.7216.829.02
Funds from Operations-21.04-40.20-26.37-22.14-28.68-37.24-11.81-19.80-21.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital14.3516.51-3.01-11.10-4.432.27-3.47-0.66-0.93
Cash from Operating Activities-6.68-23.69-29.38-33.24-33.10-34.97-15.28-20.46-22.73
Capital Expenditures-0.04-0.04-0.230.00-1.68-0.01-0.010.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.001.230.000.250.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.04-0.04-0.231.23-1.680.24-0.010.00-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.4020.9831.9132.7120.4635.627.4321.8723.76
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-3E-05
Sale of Common Pref Stock18.4020.9831.9132.7120.4635.627.4321.8723.76
Proceedsfrom Stock Options15.8718.6031.9132.7120.4633.581.8113.6623.82
Issuance or Reduction of Debt, Net-7.102.69-0.71-0.952.728.1112.06-0.100.78
Change in Long Term Debt-7.422.69-0.71-0.952.72-1.820.850.000.78
Issuance of Long Term Debt0.003.440.000.003.980.007.060.003.04
Reduction of Long Term Debt-7.42-0.75-0.71-0.95-1.26-1.82-6.210.00-2.26
Net Financing Active Other Cash Flow0.000.000.001.240.00-0.040.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.040.000.000.00
Cash from Financing Activities11.3023.6731.2032.9923.1843.6919.4921.7724.55
Exchange Rate Effect-0.19-0.11-0.050.010.02----
Net Change in Cash4.38-0.171.531.00-11.588.964.211.321.81
Free Cash Flow-6.73-23.73-29.40-33.24-33.18-34.98-15.29-20.46-22.74
Preferred Dividends (Cash Flow)---0.000.000.00--0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.5910.067.833.532.215.69
Short Term Receivables0.200.281.701.501.321.39
Inventories7.327.828.6010.6310.7210.55
Other Current Assets3.432.052.2213.7413.6612.80
Total Current Assets17.5320.2120.3429.4027.9030.44
Net Property, Plant & Equipment1.431.501.461.541.581.66
Total Investments and Advances0.000.000.320.000.000.00
Intangible Assets15.0915.5516.0217.2917.5518.01
Other Assets0.150.170.171.241.241.35
Total Assets34.1937.4338.3249.4748.2751.46
Short Term Debt Incl. Current Port. of LT Debt15.7122.3427.6323.3318.8318.91
Accounts Payable4.794.968.698.446.627.03
Other Current Liabilities4.8813.394.344.343.772.27
Total Current Liabilities25.3840.6940.6536.1229.2228.21
Long Term Debt2.6011.9715.978.5711.7019.43
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.290.530.380.420.470.51
Total Liabilities29.2753.1957.0145.1141.3948.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.002.482.482.482.48
Common Equity6.62-14.18-19.773.145.501.78
Total Shareholders Equity6.62-14.18-17.295.637.994.27
Accumulated Minority Interest-1.69-1.57-1.40-1.27-1.11-0.95
Total Equity4.92-15.75-18.694.366.883.31
Total Liabilities & Stockholders Equity34.1937.4338.3249.4748.2751.46
Book Value Per Share20.43-571.71-1,488.03447.481,888.131,387.96
Tangible Book Value Per Share-26.16-1,198.87-2,693.65-2,014.25-4,131.71-12,640.40
Full-Time Employees--47---
Price to Book Ratio0.02-0.17-0.161.370.350.90
Return on Assets-88.27-76.77-116.48-74.66-74.08-74.37
Return on Equity-498.47---370.95-296.91-423.79
Return on Invested Capital-137.64---66.95-52.85-44.16
Quick Ratio0.400.300.290.520.590.70
Current Ratio0.690.500.500.810.951.08

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-12.808.27-23.19-9.78-10.58-10.86
Depreciation0.540.520.540.560.560.55
Other Funds (Non Cash)5.791.394.632.493.211.68
Funds from Operations-6.4610.17-18.01-6.73-6.82-8.63
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.13-1.3412.522.040.621.32
Cash from Operating Activities-5.348.83-5.49-4.69-6.19-7.32
Capital Expenditures0.000.000.01-0.050.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.01-0.050.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock1.980.009.966.462.801.76
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.980.009.966.462.801.76
Proceedsfrom Stock Options1.830.007.586.462.801.76
Issuance or Reduction of Debt, Net-0.12-6.62-0.17-0.20-0.153.21
Change in Long Term Debt-0.30-6.43-0.65-0.03-0.023.40
Issuance of Long Term Debt0.000.000.000.00-0.003.45
Reduction of Long Term Debt-0.30-6.43-0.65-0.03-0.02-0.05
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.86-6.629.796.262.654.97
Exchange Rate Effect0.000.02-0.01-0.200.060.04
Net Change in Cash-3.472.234.301.32-3.48-2.31
Free Cash Flow-5.348.83-5.47-4.74-6.19-7.32

Revenue breakdown

Consolidation, Policy2024: 129.00K 2025: 172.00K
Product revenue, net2024: 11.56M 2025: 11.34M
United States2024: 11.69M 2025: 11.51M
Animal Health2024: 315.00K 2025: 353.00K
Human Health2024: 11.37M 2025: 11.16M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.21%0.2M2.2M2.90M
2026-10-157.72%0.1M1.8M2.81M
2026-09-304.89%0.1M1.7M1.20M
2026-09-154.26%0.0M0.5M16.39K
2026-08-314.75%0.0M0.3M7.98K
2026-08-142.30%0.0M0.3M7.97K
2026-07-312.01%0.0M0.3M7.34K
2026-07-151.19%0.0M0.3M6.14K
2026-06-3013.93%0.0M0.0M5.89K
2026-06-1510.39%0.0M0.0M4.59K
2026-05-2912.81%0.0M0.0M4.23K
2026-05-1518.24%0.0M0.0M2.75K
2026-04-3038.41%0.0M0.0M1.02K
2026-04-156.64%0.0M0.0M6.47K
2026-03-316.57%0.0M0.0M7.32K
2026-03-1319.65%0.0M0.0M7.26K
2026-02-2714.82%0.0M0.0M7.13K
2026-02-1317.47%0.0M0.0M7.04K
2026-01-3025.48%0.0M0.0M6.96K
2026-01-1528.04%0.0M0.0M1.38K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09424B5SEC
2026-11-09424B3SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-05EFFECTEffectiveness filing by commission orderSEC
2026-11-03S-3/ASEC
2026-11-038-KCurrent report2026-11-02SEC
2026-10-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-288-KCurrent report2026-10-27SEC
2026-10-22S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-08DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-06SEC
2026-10-058-KCurrent report2026-09-30SEC
2026-09-29PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-258-KCurrent report2026-09-23SEC
2026-09-24424B5SEC
2026-09-248-KCurrent report2026-09-23SEC
2026-09-24SCHEDULE 13G/ASEC
2026-09-218-KCurrent report2026-09-15SEC
2026-09-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-23SEC
2026-09-158-KCurrent report2026-09-11SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-048-KCurrent report2026-09-04SEC
2026-09-03424B5SEC
2026-08-21424B3SEC
2026-08-198-KCurrent report2026-08-19SEC
2026-08-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14EFFECTEffectiveness filing by commission orderSEC
2026-08-14NT 10-Q2026-06-30SEC
2026-08-11POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITIGROUP INC0.38%
Tower Research Capital LLC0.19%
UBS Group AG0.10%
Farther Finance Advisors, LLC0.01%
BARCLAYS PLC0.01%
ROYAL BANK OF CANADA0.00%
SBI Securities Co., Ltd.0.00%
WELLS FARGO & COMPANY/MN0.00%
Leonteq Securities AG0.00%
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.28%
Fidelity Total Market Index Fund0.00%
Fidelity Series Total Market Index Fund0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. JAGX. Cached 15 minutes.

Some panels did not load: insider.